Moderna vaccine added to COVID-19 booster arsenal

The provisional tick for the mRNA vaccine comes as UK data show heterologous schedules are ‘non-inferior’

A major study shows a booster dose of Moderna’s mRNA COVID-19 vaccine in a heterologous schedule increases immunogenicity compared with a homologous regime.


Neutralising antibodies are lower, however, with use of the Novavax protein-based vaccine as a booster.

The results are timely for GPs as the TGA announced on Wednesday it had provisionally approved the use of Moderna's Spikevax as a booster shot for adults following any of the primary courses approved in Australia.

The UK-based Com-COV2 study tested